Для того, чтобы увидеть эту страницу на русском языке, нажмите здесь

Click here for Russian

Selecta Russia's mission is to build a robust clinical pipeline of immunology related therapies consisting of Selecta's proprietary Synthetic Vaccine Particles (SVP™) technology and clinical stage compounds in-licensed from biotech and pharmaceutical companies.Our activities in Russia support Selecta Biosciences' goals of expanding its portfolio of immunotherapies and accelerating its clinical development, while recognizing the specific requirements of Russian patients. Selecta Russia R&D programs are developed in close coordination with Selecta in Boston.

The establishment of Selecta in Russia is aligned with the Russian Government's Pharma 2020 efforts to support local companies to develop and produce innovative medicines and provide access to the latest therapies for the benefit of patients both in Russia and worldwide. Selecta Russia has built a network of partners in governmental organization and Russian pharmaceutical companies. 

Throughout 2012, Selecta Russia has recruited a world-class team with scientists hired from top tier pharmaceutical companies and academic institutions. The team has built a full-fledged R&D facility and initiated work on several programs, including the next trials for Selecta’s nicotine vaccine. Selecta Russia has built manufacturing capacity to produce laboratory supply of SVP™ nanoparticles. The longer term objective is to operate  GLP and GMP approved facilities for the production of SVP™ nanoparticles and to support third parties customers and licensors. 

Russian and international companies and scientific institutions, who are interested in collaborating with us, are welcome to contact us under (bd@selectabio.com).

Selecta Russia is a wholly-owned subsidiary of Selecta Biosciences, Inc and was founded in 2011 as a result of Selecta’s partnership with Rusnano.